Other

University Technologies International, Inc.

Mogam Biotechnology Research Institute

Korea Greencross Corporation

Holomed Pharmaceuticals, Ltd.

Green Cross Vaccine Corporation

Eastwood Biomedical Research, Inc.

Ji-Won Yoon

Hee-Sook Jun

Noriaki Tanaka

Naoya Kobayashi

Teru Okitsu

Seungjin Shin

Hyun Chul Lee

Su-Jin Kim

Soo-il Chung

Hang-Cheol Shin

Hae-joon Park

Hee Sook Jun

Young-Ju Ha

Kyung Sup Kim

Jong Seong Ahn

Tomoyuki Kawamura

Yup Kang

Seung Shi Ham

The present invention provides a cell line which can be substituted for &#x3b2; cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.

Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity

Insulin-secreting immortalized liver cell line modified by glucose sensitivity

A vaccine including recombinant vaccinia virus (ATCC VR-1354) having an inserted gene for coding glutamic acid decarboxylase is used for preventing type 1 diabetes mellitus. The glutamic acid decarboxylase expressed from the recombinant virus suppresses or tolerizes the autoreactive T cell, and induces immunological tolerance, thus effectively prevents or delays the development of type 1 diabetes mellitus.

Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase

The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from and

Medicinal herbal compounds for the prevention and treatment of diabetes

The subject matter of the invention is directed to a single-chain insulin analog that is used to treat diabetes by gene therapy methods.

Single-chain insulin analog and a polynucleotide sequence encoding the analog

DNA and peptides of a diabetes-specific endogenous retrovirus

Portulaca oleracea has been used throughout history for many different medicinal purposes. This invention is directed to the novel use of P. oleracea for the treatment of cancer. More specifically it is disclosed that P. oleracea has a specific and distinct effect on the inhibition and/or suppression of gastric tumor cell growth in vitro and in vivo. An aqueous extract of P. oleracea showed a tumoricidal activity against KATO III (human gastric carcinoma cell line) and COLO 320 HSR cells (human colon adenoma cell line) in a dose-dependent and time-dependent manner, but not against the non-tumorous cell lines, L929 (murine lung connective tissue) and W138 (human lung diploid cell) cells. Subcutaneous injection of six week old CD1 nude mice with COLO 320 HSR cells and subsequently Portulaca oleracea extract showed a clear inhibition of tumor growth as compared to the control nude mice which received only COLO 320 HSR cells.

Portulaca oleracea and tumor cell growth

The present invention provides a method for manufacture of proinsulin with high export yield, by modifying the connecting peptide region of the proinsulin. According to the method of the present invention, the highest export yield of proinsulin can be obtained, when its connecting peptide region is similar in size to that of human insulin-like growth factor I(hIGFI) or when most of the connecting peptide region of the proinsulin is deleted.

Method for manufacture of proinsulin with high export yield

This invention provides a method for preventing and/or treating diabetes in a mammal in need thereof comprising administering to the mammal an effective amount of at least one compound of the formula I: ##STR1## The invention also provides methods for preventing and/or treating diabetes comprising administering an effective amount of at least one compound of the formula I previously set forth and Orthosiphon Arestatus.

Diabetes prevention and treatment using gamma-pyrones

This invention provides a method for preventing or treating type I diabetes in a mammal comprising administering the mammal an effective amount of at least one compound of the formula I: ##STR1## The invention also provides pharmaceutical preparations useful for the prevention and/or treatment of type I diabetes comprising an effective amount of at least one compound of the formula previously set forth and a pharmaceutically acceptable carrier.

Diabetes prevention and treatment

Growing community of inventors

Calgary, Canada

Ji-Won Yoon